Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 318 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Escitalopram Clear all
Terminated Phase 3 Interventional

Treatment of Depression With Quetiapine

NCT00174603
View directory record Official record
Conditions
Major Depression With Psychotic Features
Interventions
quetiapine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 9, 2008 · Synced Jul 22, 2026, 8:13 PM EDT
Completed Phase 4 Interventional Results available

DECIFER: Depression and Citalopram In First Episode Recovery

NCT01041274
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder
Interventions
Citalopram, Placebo, Psychoeducation, Cognitive Behavioral Therapy (CBT), Functional Magnetic Resonance Imaging (fMRI)
Drug · Behavioral · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 40 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 22, 2026, 8:13 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of ABT-436 in Major Depressive Disorder

NCT01741142
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ABT-436, Escitalopram, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
18
States / cities
Little Rock, Arkansas • Garden Grove, California • National City, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Jul 22, 2026, 8:13 PM EDT
Completed Phase 4 Interventional Results available

Advancing Personalized Antidepressant Treatment Using PET/MRI

NCT02623205
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Jul 22, 2026, 8:13 PM EDT
Completed No phase listed Observational Results available

STAR*D Alcohol: Treatment of Depression Concurrent With Alcohol Abuse

NCT00369746
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
citalopram
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Jul 22, 2026, 8:13 PM EDT
Terminated Phase 3 Interventional Results available

Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon

NCT00642694
View directory record Official record
Conditions
Major Depressive Disorder, Insomnia
Interventions
Escitalopram, Ramelteon, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Jul 22, 2026, 8:13 PM EDT
Completed No phase listed Observational

Impact of Caregiver Depression on Asthma in the Child

NCT00223288
View directory record Official record
Conditions
Depressive Disorder, Major, Asthma
Interventions
Lexapro
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
175 participants
Timeline
2003 – 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2011 · Synced Jul 22, 2026, 8:13 PM EDT
Completed Phase 2 Interventional Results available

Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant

NCT00905424
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + SPD489 (lisdexamfetamine dimesylate), Antidepressant + placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
Newport Beach, California • San Diego, California • Bradenton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Jul 22, 2026, 8:13 PM EDT
Not listed Phase 1 Interventional

Monoaminergic Modulation of Motor Function in Subacute Incomplete Spinal Cord Injury (SCI)

NCT01753882
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Lexapro, Placebo
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2019 · Synced Jul 22, 2026, 8:13 PM EDT
Completed No phase listed Observational

EEG Biomarkers for Predicting Response to Antidepressant Therapy

NCT00289523
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Medtronic - MITG
Industry
Eligibility
21 Years to 75 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Torrance, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Jul 22, 2026, 8:13 PM EDT
Completed Phase 4 Interventional

Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro)

NCT00296790
View directory record Official record
Conditions
Insomnia
Interventions
zolpidem tartrate
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years to 64 Years
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 11, 2007 · Synced Jul 22, 2026, 8:13 PM EDT
Completed Phase 4 Interventional Results available

Connectivity Affecting the Antidepressant REsponse Study

NCT02332291
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Bupropion XL
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Jul 22, 2026, 8:13 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

NCT00406640
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Disorder, Major
Interventions
Desvenlafaxine succinate sustained-release (DVS SR), Escitalopram
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
52
States / cities
Peoria, Arizona • Pasadena, California • San Diego, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Jul 22, 2026, 8:13 PM EDT
Completed Phase 2 Interventional

Serotonin, Impulsivity, and Cocaine Dependence Treatment

NCT00297505
View directory record Official record
Conditions
Cocaine Dependence
Interventions
citalopram
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 22, 2026, 8:13 PM EDT
Completed Phase 4 Interventional Results available

A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder

NCT03924323
View directory record Official record
Conditions
Anxiety Disorders,Generalized Anxiety Disorder
Interventions
Escitalopram, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
7 Years to 17 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
39
States / cities
Dothan, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Jul 22, 2026, 8:13 PM EDT
Completed Phase 3 Interventional

Serotonergic Pharmacotherapy for Agitation of Dementia

NCT00009204
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Dementia, Vascular
Interventions
Citalopram [Celexa], Perphenazine [Trilafon]
Drug
Lead sponsor
Bruce Pollock
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Jul 22, 2026, 8:13 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)

NCT04623099
View directory record Official record
Conditions
Anxiety
Interventions
Escitalopram
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 17 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Jul 22, 2026, 8:13 PM EDT
Withdrawn Phase 1 Interventional

Enhancing Processing Speed and Executive Functioning in Depressed Older Adults With Computerized Cognitive Training

NCT04836533
View directory record Official record
Conditions
Depression in Old Age, Depression
Interventions
Experimental: Computerized Cognitive Training, Experimental: Open-label antidepressant treatment, Active Comparator: Solitaire Training, Placebo Comparator: Placebo-controlled antidepressant treatment
Other · Drug
Lead sponsor
Queens College, The City University of New York
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Jul 22, 2026, 8:13 PM EDT
Completed Phase 2 Interventional Results available

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

NCT04437485
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions
Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Jul 22, 2026, 8:13 PM EDT
Completed Not applicable Interventional Results available

Efficacy and Feasibility of a Personalized Treatment for Depression With Co-Occurring Anxiety

NCT00930293
View directory record Official record
Conditions
Depression, Anxiety
Interventions
Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS), Brief Supportive Psychotherapy (BSP), Citalopram hydrobromide
Behavioral · Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Jul 22, 2026, 8:13 PM EDT
Completed Phase 3 Interventional

Citalopram in Treating Postmenopausal Women With Hot Flashes

NCT00363909
View directory record Official record
Conditions
Breast Cancer, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment
Interventions
citalopram hydrobromide, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
198
States / cities
Augusta, Georgia • Aurora, Illinois • Bloomington, Illinois + 126 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Jul 22, 2026, 8:13 PM EDT
Completed Phase 2 Interventional

Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease

NCT04497168
View directory record Official record
Conditions
Parkinson Disease
Interventions
Citalopram 20mg, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
65 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jul 22, 2026, 8:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Citalopram HBr 10 mg Tablets Under Fasting Conditions

NCT00865943
View directory record Official record
Conditions
Healthy
Interventions
Citalopram HBr eq. 10 mg tablets, single dose, CELEXATM 10 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Jul 22, 2026, 8:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Aripiprazole and Lexapro Drug Interaction Study

NCT00361790
View directory record Official record
Conditions
Healthy
Interventions
Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Jul 22, 2026, 8:13 PM EDT